Drug Profile
BMS 986207
Alternative Names: Anti-TIGIT antibody - Bristol Myers Squibb; BMS-986207; ONO-4686Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Compugen; Multiple Myeloma Research Consortium; Ono Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Multiple myeloma; Solid tumours
Most Recent Events
- 25 Jan 2024 Bristol-Myers Squibb completes a phase I/II trial in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA, Australia, Argentina, Canada, Chile, Japan, Romania and Singapore (Parenteral) (NCT02913313)
- 25 Jan 2024 Bristol-Myers Squibb completes a phase I/II trial in Solid tumours (Second-line therapy or greater, Monotherpay, Late-stage disease) in USA, Australia, Argentina, Canada, Chile, Japan, Romania and Singapore (Parenteral) (NCT02913313)
- 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)